153 related articles for article (PubMed ID: 23561982)
21. Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study.
van Beilen M; Portman AT; Kiers HA; Maguire RP; Kaasinen V; Koning M; Pruim J; Leenders KL
Parkinsonism Relat Disord; 2008; 14(3):224-8. PubMed ID: 18249027
[TBL] [Abstract][Full Text] [Related]
22. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
[TBL] [Abstract][Full Text] [Related]
23. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex.
Kaasinen V; Nurmi E; Brück A; Eskola O; Bergman J; Solin O; Rinne JO
Brain; 2001 Jun; 124(Pt 6):1125-30. PubMed ID: 11353728
[TBL] [Abstract][Full Text] [Related]
24. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity.
Hilker R; Schweitzer K; Coburger S; Ghaemi M; Weisenbach S; Jacobs AH; Rudolf J; Herholz K; Heiss WD
Arch Neurol; 2005 Mar; 62(3):378-82. PubMed ID: 15767502
[TBL] [Abstract][Full Text] [Related]
25. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
[TBL] [Abstract][Full Text] [Related]
26. Brain dopaminergic modulation associated with executive function in Parkinson's disease.
Farid K; Sibon I; Guehl D; Cuny E; Burbaud P; Allard M
Mov Disord; 2009 Oct; 24(13):1962-9. PubMed ID: 19672989
[TBL] [Abstract][Full Text] [Related]
27. Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease.
Ko JH; Antonelli F; Monchi O; Ray N; Rusjan P; Houle S; Lang AE; Christopher L; Strafella AP
Hum Brain Mapp; 2013 Jul; 34(7):1591-604. PubMed ID: 22331665
[TBL] [Abstract][Full Text] [Related]
28. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
29. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography.
Ouchi Y; Yoshikawa E; Okada H; Futatsubashi M; Sekine Y; Iyo M; Sakamoto M
Ann Neurol; 1999 May; 45(5):601-10. PubMed ID: 10319882
[TBL] [Abstract][Full Text] [Related]
30. Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.
Picco A; Morbelli S; Piccardo A; Arnaldi D; Girtler N; Brugnolo A; Bossert I; Marinelli L; Castaldi A; De Carli F; Campus C; Abbruzzese G; Nobili F
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1062-70. PubMed ID: 25820675
[TBL] [Abstract][Full Text] [Related]
31. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
Huang WS; Chiang YH; Lin JC; Chou YH; Cheng CY; Liu RS
J Nucl Med; 2003 Jul; 44(7):999-1005. PubMed ID: 12843212
[TBL] [Abstract][Full Text] [Related]
32. The longitudinal associations between cognition, mood and striatal dopaminergic binding in Parkinson's Disease.
Bayram E; Kaplan N; Shan G; Caldwell JZK
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2020 Jul; 27(4):581-594. PubMed ID: 31411534
[TBL] [Abstract][Full Text] [Related]
33. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study.
Ekman U; Eriksson J; Forsgren L; Mo SJ; Riklund K; Nyberg L
Lancet Neurol; 2012 Aug; 11(8):679-87. PubMed ID: 22742929
[TBL] [Abstract][Full Text] [Related]
34. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease.
Siepel FJ; Brønnick KS; Booij J; Ravina BM; Lebedev AV; Pereira JB; Grüner R; Aarsland D
Mov Disord; 2014 Dec; 29(14):1802-8. PubMed ID: 25284687
[TBL] [Abstract][Full Text] [Related]
35. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
[TBL] [Abstract][Full Text] [Related]
36. Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities.
Biundo R; Formento-Dojot P; Facchini S; Vallelunga A; Ghezzo L; Foscolo L; Meneghello F; Antonini A
J Neurol Sci; 2011 Nov; 310(1-2):64-9. PubMed ID: 21862438
[TBL] [Abstract][Full Text] [Related]
37. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
Song IU; Chung YA; Oh JK; Chung SW
Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
[TBL] [Abstract][Full Text] [Related]
38. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease.
Zgaljardic DJ; Borod JC; Foldi NS; Mattis PJ; Gordon MF; Feigin A; Eidelberg D
J Clin Exp Neuropsychol; 2006 Oct; 28(7):1127-44. PubMed ID: 16840240
[TBL] [Abstract][Full Text] [Related]
39. Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease.
Kalbe E; Voges J; Weber T; Haarer M; Baudrexel S; Klein JC; Kessler J; Sturm V; Heiss WD; Hilker R
Neurology; 2009 Jan; 72(1):42-9. PubMed ID: 19122029
[TBL] [Abstract][Full Text] [Related]
40. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia.
Meyer-Lindenberg A; Miletich RS; Kohn PD; Esposito G; Carson RE; Quarantelli M; Weinberger DR; Berman KF
Nat Neurosci; 2002 Mar; 5(3):267-71. PubMed ID: 11865311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
